Trial Profile
A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms NEORAD
- 01 Mar 2023 Results published in the Clinical Oncology
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results of an exloratory analysis (n=25) presented at the 42nd European Society for Medical Oncology Congress.